HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 88.74% from the company’s current price. HC Wainwright also issued estimates for TG Therapeutics’ FY2025 earnings at $1.26 EPS.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $29.14 on Wednesday. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market cap of $4.54 billion, a price-to-earnings ratio of -291.37 and a beta of 2.24. The firm has a 50 day simple moving average of $31.69 and a 200 day simple moving average of $25.63.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period last year, the business earned $0.73 EPS. The company’s revenue was down 49.4% compared to the same quarter last year. Research analysts predict that TG Therapeutics will post 0.07 earnings per share for the current fiscal year.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,358 shares of company stock worth $781,497 over the last quarter. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. NBC Securities Inc. boosted its holdings in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in TG Therapeutics during the 3rd quarter valued at $53,000. Values First Advisors Inc. acquired a new position in TG Therapeutics during the third quarter worth $58,000. Finally, GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,171 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.